SCHEMBL3300302

SCHEMBL3300302

COc1ccc(CNc2nc3c(c(=O)n2-c2ccccc2)CN(C(=O)Nc2ccc(F)c(Cl)c2)CC3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 5/20 0.47
RECQL P46063 1/20 0.42
MAPT P10636 6/20 0.42
ALDH1A1 P00352 4/20 0.42
TP53 P04637 1/20 0.42
PDE5A O76074 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CLPP Q16740 1/20 0.41
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDR P35968 1/20 0.40
CDK1 P06493 1/20 0.39
IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296514 0.94 PRLHR (0.47) PRLHRRECQLMAPTALDH1A1PDE5A
SCHEMBL3298474 0.94 PRLHR (0.45) PRLHRRECQLMAPTALDH1A1PDE5A
SCHEMBL3297256 0.93 PRLHR (0.48) PRLHRRECQLMAPTALDH1A1PDE5A
SCHEMBL3296930 0.92 PDE5A (0.51) PRLHRRECQLMAPTALDH1A1PDE5A
SCHEMBL3303376 0.92 PRLHR (0.44) PRLHRRECQLMAPTALDH1A1PDE5A
SCHEMBL3297316 0.91 PRLHR (0.46) PRLHRRECQLMAPTALDH1A1TP53
SCHEMBL3297770 0.91 PRLHR (0.50) PRLHRRECQLMAPTALDH1A1PDE5A
SCHEMBL3297467 0.90 PRLHR (0.45) PRLHRRECQLMAPTALDH1A1CLPP
SCHEMBL3298674 0.90 PRLHR (0.47) PRLHRRECQLMAPTALDH1A1PDE5A
SCHEMBL3300656 0.90 PRLHR (0.52) PRLHRMAPTALDH1A1PDE5AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 PRLHR 3093/4885RECQL 1541/4885MAPT 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.